HMA-EMA AI workplan and its 2 linked instruments

How to read this page

Details: Guide Definitions: every term and label explained

HMA-EMA AI workplanEU AI ActEMA AI reflection paper
AuthorityEMAEuropean UnionEMA
Legal weightGuidance & Q&ALaw & regulationGuidance & Q&A
StatusFinalEffective · phasedFinal
Last verifiedNot yetNot yetNot yet
Summary

Joint HMA and EMA workplan for artificial intelligence in medicines regulation, 2023 to 2028. It is a plan, not a requirement.

Horizontal EU law on AI systems, applying in phases. AI literacy duties already apply; transparency duties (Art. 50) apply from 2 August 2026. The 2026 digital omnibus moved high-risk obligations to December 2027 (Annex III) and August 2028 (Annex I, e.g. devices).

EMA's current thinking on AI and machine learning for human and veterinary medicines, covering principles that apply at any stage of a medicine's lifecycle, from drug discovery to after authorisation.

Lifecycle
  • 18 Dec 2023 Published
  • 1 Aug 2024 Entered into force (obligations phased)
  • 27 Jul 2026 Digital Omnibus on AI, Regulation (EU) 2026/1744, in force (published in the Official Journal 24 Jul 2026); defers high-risk obligations
  • 2 Aug 2026 Article 50 transparency duties apply (Art. 50(2) marking for systems already on the market: 2 Dec 2026, per the Omnibus)
  • Target 2 Dec 2027 Annex III high-risk obligations apply
  • Target 2 Aug 2028 Annex I (product-embedded, e.g. devices) high-risk obligations apply
  • 19 Jul 2023 Draft released for public consultation
  • 31 Dec 2023 Public consultation closed
  • 9 Sep 2024 Final version adopted by CHMP
  • 30 Sep 2024 Final version published
SourceOfficial text
Source: EMA.
Official text
Source: European Union. Licensed under CC BY 4.0.
Official text
Source: EMA.

These facts are placed side by side from each record. This page does not say which is stricter or whether requirements differ. Read the official texts.